Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Alabama at Birmingham
With
GlaxoSmithKline
Age
19–90
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologic diagnosis of epithelial ovarian or primary peritoneal cancer
Measurable disease or evaluable disease with CA125 \>100
One prior treatment with taxane/platinum based chemotherapy, but patients with recurrent ovarian cancer not receiving platinum-based chemotherapy at time of initial diagnosis will be allowed
Recurrence after treatment free interval of at least 6 mos from completion of primary chemotherapy
19 years of age or older
Life expectancy of greater than 12 weeks
Performance status of 0, 1 or 2 (based on GOG Performance Status)
Normal bone marrow, renal and hepatic function based upon lab tests
Cardiac ejection fraction within institutional normal range
Ability to swallow and retain oral medication
Ability to understand a written informed consent document
You may not be if
Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering study
Epithelial ovarian tumors of low malignant potential, stromal or germ cell origin
Non-measurable or non-evaluable disease
Archived tumor tissue not available for assay
Patients may not be receiving any other investigational agents or concurrent anticancer therapy, or herbal (alternative) medicines
Patients with known brain metastases
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
